Company newsCompany release
Johnson & Johnson agrees to acquire Ollin Biosciences
Johnson & Johnson said the upfront payment is $2.2 billion, with potential additional regulatory and commercial milestone payments.
GetSignal
Johnson & Johnson said on November 16, 2026 that it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.
Key facts
- Upfront payment
- $2.2 billion
- Target
- Ollin Biosciences, Inc.
- Target stage
- Clinical-stage
- Additional payments
- Potential regulatory and commercial milestone payments
Source: The company's release on Business Wire, November 16, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
Johnson & Johnson first, then the newest- Johnson & Johnson says CAPLYTA improved manic symptoms in second Phase 3 study
JNJ · Johnson & Johnson · Company release · Nov 10, 2026
- Johnson & Johnson presents early Phase 1 data on prostate cancer combination
JNJ · Johnson & Johnson · Company release · Nov 8, 2026
- Johnson & Johnson presents new patient experience data on nipocalimab in Sjögren's disease
JNJ · Johnson & Johnson · Company release · Nov 7, 2026
